MedTrace Logo

Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

NCT04469777 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-04-01

No results posted yet for this study

Summary

This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Conditions

  • Optic Neuropathy

Interventions

DRUG

erythropoietin

Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mai ElBahwash, PhD · Alexandria Faculty of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-12-15
Completion
2020-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469777 on ClinicalTrials.gov